. Kinases identified by LC-MS/MS using the photoaffinity labels 1a and 2a ........ S22 Table S4 . Proteins identified by LC-MS/MS using the photoaffinity labels 4a and 5a ........ S23 Table S5 Figure S9 . Model studies of the quenching reactions between 100 µM S4 and 10 mM (a) L-serine, (b) L-glutamic acid, (c) β-mercaptoethanol, and (d) glutathione in acetonitrile/PBS (1:1, 70 mM Cl  , pH 7.5) after 5-min 302 nm photoirradiation. (e) Quenching of probe 1a (100 µM) by 10 mM glutathione in acetonitrile/PBS (1:1, 70 mM Cl  , pH 7.5) after 5-min 302 nm photoirradiation. For HPLC chromatogram, red trace = absorbance at 254 nm; blue trace = absorbance at 365 nm. While L-serine and L-glutamic acid cannot compete effectively with the chloride quenching, β-mercaptoethanol and glutathione can form covalent adducts with the in situ generated carboxynitrile imine based on HPLC traces. However, the thiol-adduct masses were not detectable in (c) and (d), but detectable in (e), presumably due to differences in ionization potential of the adducts. Figure S11. Western blot detection of the targets after the photoaffinity label-mediated crosslinking and subsequent pulldown. (a) Western blot of BTK, Src and Csk in the pull-downed samples using a mixture of anti-BTK, anti-Src, and anti-Csk antibodies followed by detection with an IR dye-conjugated secondary antibody. (b) Western blot of BRD4 in the pull-downed samples using an anti-BRD4 antibody followed by detection with an IR dye-conjugated secondary antibody. 
General Information
Recombinant human BTK protein used in the in-gel fluorescence experiments was purchased from Thermo Fisher (Cat. No. PR5442A). Recombinant human BTK (387-659) was used in the LC-MS based cross-linking experiments. Recombinant human BRD4 (44-168) protein used in the in-gel fluorescence and LC-MS studies was purchased from Active Motif (Cat. No. 31380). Solvents and chemicals were purchased from commercial sources and used directly without further purification.
Flash chromatography was performed with SiliCycle P60 silica gel (40-63 μm, 60 Å). 1 H NMR spectra were recorded with Varian Mercury-300, Inova-400 or -500 MHz spectrometers at University at Buffalo and Agilent 400-MR, Varian Inova 500 MHz, Varian VNMRS 500 MHz, Bruker Avance III 500 MHz at Abbvie. Chemical shifts were reported in ppm using either TMS or deuterated solvents as internal standards (TMS, 0.00; CDCl3, 7.26; CD3OD, 3.31; DMSO-d6, 2.50). Multiplicity was reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, brs = broad.
13 C NMR spectra were recorded at 75.4 or 126 MHz, and chemical shifts were reported in ppm using deuterated solvents as internal standards (CDCl3, 77.0; DMSO-d6, 39.5; CD3OD, 49.05). High resolution mass spectrometry was performed on a Bruker solariX XR Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR-MS). In-gel fluorescence images were acquired by scanning SDS-PAGE gels with a BioRad PharosFX imager. Invitrogen PVDF membranes were used for western blots and scanned using Licor. For photoirradiation with a hand-held UV lamp, if not specified, 5 min 302-nm photoirradiation was carried out for ACT probes, 10 min 365-nm photoirradiation was carried out for DA probes, and 10 min 302-nm photoirradiation was carried out for BP probes.
Experimental Procedures and Characterization Data
Scheme S1. Synthesis of the alkyne-functionalized ACT photo-affinity label N-(But-3-yn-1-yl)-2-chloroacetamide (S1): To a solution of but-3-yn-1-amine (250 mg, 3.62 mmol) and ethyldiisopropylamine (561 mg, 4.34 mmol) in 25 mL CH2Cl2 cooled in ice-water bath was added dropwise a solution of 2-chloroacetyl chloride (490 mg, 4.34 mmol) in 5 mL CH2Cl2. The ice-water bath was removed, and the mixture was stirred at r.t. for 3 h. Afterwards, additional 20 mL CH2Cl2 was added, and the organic layer was washed successively with 20 mL saturated NaHCO3, 20 mL 2 N HCl and 20 mL brine, and dried over MgSO4. The solvent was then removed under reduced pressure to give the desired product as a brownish oil (427 mg, 81% yield): Rf = 
N-(But-3-yn-1-yl)-2-iodoacetamide (S2):
To a solution of S1 (415 mg, 2.85 mmol) in 15 mL acetone was added NaI (1.28 g, 8.55 mmol) , and the mixture was refluxed for 4 h. After the solvent was evaporated, the residue was redissolved in 30 mL EtOAc and 30 mL water. The organic layer was separated, washed successively with 20 mL 10% Na2S2O3, 20 mL H2O and 20 mL brine. After drying the solution over MgSO4, the solvent was removed with rotary evaporator to give the desired product as a light brown solid (471 mg, 70% yield), which was used directly without further purification 
Ethyl 2-(4-acetamidophenyl)-2H-tetrazole-5-carboxylate (S3):
A solution of 50% ethyl 2-oxoacetate in toluene (3.042 g, 14.9 mmol) and benzenesulfonyl hydrazide (1.72 g, 11.5 mmol) in 60 mL EtOH was stirred at r.t. for 1 h. The solvent was removed under reduced pressure, and the residue was re-dissolved in 60 mL pyridine. Separately, to a suspension of N-(4-aminophenyl)acetamide (1.607 g, 10.7 mmol) and 4 mL concentrated HCl in 8 mL H2O and 10 mL EtOH was added dropwise a solution of NaNO2 (0.775 g, 5.2 mmol) in 3 mL H2O at 0 °C. After 10-minute stirring, this solution was added dropwise to the previously prepared pyridine solution over 50 min at -10 °C. The mixture was warmed up to r.t. over 2 h with stirring before 100 mL H2O was added. The solution was extracted with 70 mL CH2Cl2 three times, and the organic layers were collected, combined, washed successively with 3×100 mL 2 N HCl and 1×70 mL brine. After drying over MgSO4, the solvent was removed on a rotary evaporator. The dark brown oily residue was applied to a silica gel flash chromatography using hexanes/EtOAc (1:1 → 1:4) as the eluent to give the crude product as a dark yellow oil (2.235 g). The crude product was recrystallized twice from EtOH to give the titled compound as a yellow powder (906 mg, 31% yield): Rf = 0.44 (hexanes/EtOAc = 1:4); 1 H NMR (300 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.07 (d, J = 9.1 Hz, 2H), 7.87 (d, J = 9.1 Hz, 2H), 4.46 (q, J = 7.1 Hz, 2H), 2.10 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H); 13 C NMR (75 MHz, DMSO-d6) δ 168.9, 157.2, 157. 1, 141.5, 130.6, 121.1, 119.6, 62.3, 24.1, 14.0; HRMS (ESI) [M+H] + calcd for C12H14N5O3 276.1091 [M+H] + , found 276.1094.
Ethyl 2-(4-aminophenyl)-2H-tetrazole-5-carboxylate (S4):
To a suspension acetamide derivative S3 (201 mg, 0.73 mmol) in 5 mL EtOH was added 10 drops of concentrated HCl, and the mixture was refluxed until the starting material was consumed based on thin-layer chromatography. The mixture was cooled down to -20 °C, and the precipitate was collected with a glass filter, washed with cold EtOH, and dried under vacuum to give the titled compound as an off-white powder (97 mg, 57% yield): Rf = 0.44 (hexanes/EtOAc = 1: 1, 140.3, 131.5, 121.8, 121.3, 62.3, 14.0; HRMS (ESI) 
S28
Ethyl 2-(4-((2-(but-3-yn-1-ylamino)-2-oxoethyl)amino) phenyl)-2H-tetrazole-5-carboxylate (S5): A mixture of aniline S4 (88 mg, 0.38 mmol), iodoacetamide S2 (90 mg, 0.38 mmol) and K2CO3 (156 mg, 1.13 mmol) in 3 mL MeCN was refluxed for 2 days. The mixture was filtered through a layer of celite and the solvent was removed with a rotavapor. The residue was applied to a silica gel flash chromatography using hexanes/EtOAc (1:10) as the eluent to give the desired product as an off-white powder (48 mg, 37% 5, 157.4, 156.7, 150.5, 125.4, 121.6, 112.4, 82.1, 72.2, 62.1, 46.3, 37.7, 18.7, 14.0; HRMS (ESI) 
2-(4-((2-(But-3-yn-1-ylamino)-2-oxoethyl)amino) phenyl)-2H-tetrazole-5-carboxylic acid (S6):
To a solution of tetrazole carboxylate S5 (37 mg, 0.11 mmol) in 1 mL EtOH at r.t. was added 2 mL 2 N NaOH, and the mixture was stirred at r.t. until the starting material was completely consumed based on thin layer chromatography. The solution was added 5 mL EtOAc and then acidified. The precipitate that appeared was collected with a glass filter, washed with water, and dried under vacuum to give the titled compound as an off-white powder (27 mg, 79% yield) 6, 158.8, 157.6, 150.4, 125.6, 121.5, 112.4, 82.1, 72.1, 46.3, 37.7, 18.7; HRMS (ESI) 
Synthesis of 1b:
A solution of dasatinib amine•3TFA salt S8 (15.0 mg, 0.016 mmol), tetrazole carboxylic acid S6 (6.2 mg, 0.020 mmol), HATU (7.5 mg, 0.020 mmol), HOAt (2.7 mg, 0.020 mmol), and triethylamine (9.6 L, 0.069 mmol) in 150 L DMF was stirred at r.t. overnight. The reaction mixture was applied to a medium-pressure silica gel flash chromatography system equipped with an automatic fraction collector running the MeOH/ CH2Cl2 (2:98→20:80) eluent S30 gradient. The suitable fractions were pooled and evaporated under reduced pressure. The residue was re-dissolved in 3 mL MeCN and 3 mL H2O containing 0.5% TFA, and the solution was lyophilized to dryness to give the titled compound as a white powder (7.4 mg, 41% + , found 871.3358. The product purity was also verified by analytical HPLC as shown below.
Synthesis of 2a:
A solution of dasatinib amine•3TFA salt S7 (27.1 mg, 0.033 mmol), diazirine acid S9 (8.2 mg, 0.033 mmol), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP; 17.01 mg, 0.033 mmol) and ethyldiisopropylamine (0.023 mL, 0.131 mmol) were combined in DMF (3 mL) and stirred for 2 h at r.t. The crude reaction mix was diluted with 90% DMSO/water to 4 mL and purified on preparative HPLC. The eluents were A: 0.1% TFA-water; B: acetonitrile. 0-5 min isocratic followed by 1% increase in acetonitrile per min gradient. The appropriate fractions were collected and lyophilized to dryness to give the titled compound (7.7 mg, 25% 
Synthesis of 2b:
A solution of dasatinib amine•3TFA salt S8 (10 mg, 10.90 µmol), diazirine acid S9 (7.3 mg, 0.029 mmol), PyAOP (15.15 mg, 0.029 mmol) and ethyldiisopropylamine (0.020 mL, 0.116 mmol) were combined in DMF (3 mL) and stirred for 2 h at r.t. The crude reaction mix was diluted with 90% DMSO/water to 4 mL and purified preparative HPLC. The eluents were A: 0.1% TFA-water; B: acetonitrile. 0-5 min isocratic; 1%/min acetonitrile gradient. The appropriate fractions were collected and lyophilized to dryness to give the titled compound (8.8 mg, 38% 
